Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | TP53 L194F |
Gene Variant Detail | |
Relevant Treatment Approaches | p53 Activator p53 Gene Therapy |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
TP53 L194F | breast cancer | sensitive | Tanespimycin + Vorinostat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tanespimycin (17-AAG) and Zolinza (vorinostat) were synergistic towards tumor growth inhibition in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). | 26009011 | |
TP53 L194F | breast cancer | sensitive | Tanespimycin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). | 26009011 | |
TP53 L194F | breast cancer | sensitive | Vorinostat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Zolinza (vorinostat) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). | 26009011 | |
TP53 L194F | breast cancer | sensitive | Ganetespib | Preclinical - Cell culture | Actionable | In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PMID: 26009011). | 26009011 |